Clinical trials: Hepatitis A
Chronic Hepatitis C Virus Infection
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy
HRN-003 STUDY SYNOPSIS OBJECTIVE: To compare the Sustained Virologic Response (SVR) of PEGIntron plus ribavirin among patients receiving a fixed dose of PEGIntron versus weighted-adjusted dosing.
- Trial name
- NCT00215865
- Testing
- PEGIntron plus ribavirin
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Hepatitis Resource Network
Hepatitis B, Liver Neoplasms
Qidong Hepatitis B Intervention Study
During 1983-1990 in the Jiangsu province of China, 80,000 infants were randomised by area of birth between control, standard Hepatitis B vaccination (at 0, 1 and 6 months of age) and standard vaccination plus a booster dose at…
- Conditions
- Hepatitis B, Liver Neoplasms, Liver Diseases
- Trial name
- NCT00222664
- Testing
- Hep-V Vax
- Where
- 3 sites in China, United Kingdom
- Volunteers
- 80,000 people
- Sponsor
- University of Oxford
Chronic Hepatitis C
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.
- Trial name
- NCT00209755
- Testing
- therapeutic drug monitoring of ribavirin and dose adaptation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital A Michallon
Porphyria Cutanea Tarda
Risk Factors of Porphyria Cutanea Tarda (PCT)
Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.
- Trial name
- NCT00213772
- Volunteers
- 280 people
- Sponsor
- University Hospital, Strasbourg, France
Hepatitis B, Vaccine
Antibody Response and Immune Memory 15-18 Years After HBV Vaccination
Taiwan is an endemic region for hepatitis B. Before the implementation of a nationwide vaccination program in 1984, the hepatitis B virus (HBV) carrier rate in the general population was 15 to 20%.1-2 The major impact of…
- Trial name
- NCT00172328
- Testing
- Hepatitis B vaccine
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00157534
- Testing
- Celgosivir
- Volunteers
- 43 people
- Sponsor
- BioWest Therapeutics Inc
Chronic Hepatitis C
Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients
Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C
- Trial name
- NCT00146016
- Testing
- Amantadine
- Where
- Netherlands
- Volunteers
- 390 people
- Sponsor
- UMC Utrecht
Hepatitis C, Chronic
Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)
This was a randomized, multi-center, partially placebo-controlled Phase IV study to compare the efficacy and tolerability of a 48-week combined therapy with pegylated interferon alpha-2a, ribavirin and amantadine sulphate versus…
- Trial name
- NCT00127777
- Testing
- Amantadine sulphate (in addition to standard treatment)
- Volunteers
- 700 people
- Sponsor
- University Hospital, Saarland
Hepatitis C, Chronic
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.
- Trial name
- NCT00122629
- Testing
- peg-interferon alfa-2b, ribavirin, amantadine
- Where
- France
- Volunteers
- 405 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C. II.
- Trial name
- NCT00004804
- Testing
- interferon alfa
- Volunteers
- 57 people
- Sponsor
- National Center for Research Resources (NCRR)
Hepatitis B
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.
The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.
- Trial name
- NCT00044135
- Testing
- clevudine (drug)
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 30 people
- Sponsor
- Triangle Pharmaceuticals
Infant, Premature
Vitamin A Supplementation in Preterm Infants
Extremely low birth weight infants have decreased blood levels of Vitamin A. This Vitamin A deficiency may increase the risk of infections and chronic lung disease in these infants.
- Trial name
- NCT00063596
- Testing
- Vitamin A supplementation
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hepatitis C
12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
This is a multi-center study. Neither the study subjects nor the physicians will know what treatment an individual subject is receiving. Subjects will be randomly assigned (like flipping a coin) to one of five treatment groups.
- Trial name
- NCT00069511
- Testing
- UT-231B
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- United Therapeutics